EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pardes Biosciences's enterprise value is $-19.25 Mil.
Pardes Biosciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-82.88 Mil. Therefore, Pardes Biosciences's EV-to-EBITDA for today is 0.23.
The historical rank and industry rank for Pardes Biosciences's EV-to-EBITDA or its related term are showing as below:
PRDS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -59.13 Med: 0 Max: 2.47
Current: 0.23
During the past 3 years, the highest EV-to-EBITDA of Pardes Biosciences was 2.47. The lowest was -59.13. And the median was 0.00.
PRDS's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.57
vs PRDS: 0.23
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Pardes Biosciences EV-to-EBITDA Historical Data
The historical data trend for Pardes Biosciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pardes Biosciences's EV-to-EBITDA
For the Biotechnology subindustry, Pardes Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pardes Biosciences's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pardes Biosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pardes Biosciences's EV-to-EBITDA falls into.
Pardes Biosciences's current Enterprise Value is $-19.25 Mil.
Pardes Biosciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-82.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Pardes Biosciences's PE Ratio for today is calculated as:
Pardes Biosciences's share price for today is $2.16.
Pardes Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.290.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Pardes Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Pardes Biosciences (Pardes Biosciences) Business Description
Pardes Biosciences Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel oral-antiviral therapeutics to improve the lives of patients suffering from life-threatening disease, starting with the lead product candidate, pomotrelvir (formerly known as PBI-0451), which is in clinical development and intended to treat COVID-19 in adult and pediatric patients. COVID-19 is caused by infection with the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Pomotrelvir inhibits the main coronaviral cysteine protease, a viral protein essential for the replication of all known coronaviruses, including SARS-CoV-2.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRDS has been successfully added to your 